Baricitinib for the Lung Injury Following Spontaneous SAH

Baricitinib will be administered orally (or crushed for nasogastric tube delivery) at a daily dosage of 4mg for three consecutive days following SAH.

Participants will receive standard treatment and care according to the current management guidelines for subarachnoid hemorrhage.